AbbVie (ABBV) News Today → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free abbv Stock Alerts $158.00 -9.29 (-5.55%) (As of 01:39 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAbbVie (NYSE:ABBV) Releases Earnings Results, Beats Expectations By $0.11 EPSmarketbeat.com - April 26 at 1:21 PMABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q1 2024investorplace.com - April 26 at 1:08 PMBank of New Hampshire Sells 7,211 Shares of AbbVie Inc. (NYSE:ABBV)marketbeat.com - April 26 at 1:01 PMAbbVie Q1 Profit Increases, beats estimatesmarkets.businessinsider.com - April 26 at 9:04 AMAbbVie Lifts FY24 Outlook After Higher Q1 Results - Updatemarkets.businessinsider.com - April 26 at 9:04 AMAbbVie Lifts Outlook After 1Q Revenue Unexpectedly Risesmarketwatch.com - April 26 at 9:04 AMAbbVie raises annual profit forecast on strong Skyrizi salesyahoo.com - April 26 at 9:04 AMAbbVie Lifts 2024 Forecast as Newer Drugs Replace Humira Lossesmsn.com - April 26 at 9:04 AMAbbVie (NYSE:ABBV) Issues FY24 Earnings Guidancemarketbeat.com - April 26 at 8:49 AMAbbVie Raises Earnings Guidance Even as Humira Sales Continue to Fallbarrons.com - April 26 at 8:04 AMAbbVie’s first-quarter results top expectations as arthritis drugs fuel growthmarketwatch.com - April 26 at 8:03 AMAbbVie lifts profit forecast after Skyrizi sales beat expectationsreuters.com - April 26 at 7:44 AMAbbVie Reports First-Quarter 2024 Financial Resultsprnewswire.com - April 26 at 7:35 AMAbbVie (NYSE:ABBV) Shares Down 0.8% marketbeat.com - April 25 at 7:07 PMAbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Studymsn.com - April 25 at 6:03 PMPittenger & Anderson Inc. Boosts Stake in AbbVie Inc. (NYSE:ABBV)marketbeat.com - April 25 at 4:51 PMREFILE-AbbVie's Rinvoq shows superiority to Regeneron's Dupixent in studyfinance.yahoo.com - April 25 at 1:03 PMHere's what Wall Street expects from AbbVie's earnings reportmarkets.businessinsider.com - April 25 at 1:03 PMAbbVie's Rinvoq Shows Positive Results Over Dupixent In Atopic Dermatitis Studymarkets.businessinsider.com - April 25 at 1:03 PMAbbVie Q1 Preview: Skyrizi and Rinvoq’s launches could help Q1msn.com - April 25 at 1:03 PMAbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in studyreuters.com - April 25 at 8:48 AMCopycats take bite out of AbbVie’s best-selling Humira drugft.com - April 25 at 8:03 AMNew Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Studyprnewswire.com - April 25 at 8:00 AMMerck (MRK) vs. AbbVie (ABBV): Which Pharma Stock Will Drive Earnings Growth?stocknews.com - April 24 at 7:05 PM8,424 Shares in AbbVie Inc. (NYSE:ABBV) Bought by Wynn Capital LLCmarketbeat.com - April 24 at 6:37 PMAbbvie breaks six day winning cycle, trades in the redmsn.com - April 24 at 4:54 PMAbbVie (NYSE:ABBV) Trading Down 0.9%marketbeat.com - April 24 at 4:22 PMSchnieders Capital Management LLC Sells 5,843 Shares of AbbVie Inc. (NYSE:ABBV)marketbeat.com - April 23 at 11:25 PMDividend Growth Stars: 7 Stocks With 10-Year Double-Digit Rate Hikesinvestorplace.com - April 23 at 4:41 PMAbbVie (NYSE:ABBV) Stock Price Up 1.3%marketbeat.com - April 23 at 2:58 PMAllergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brandsfinance.yahoo.com - April 23 at 9:36 AMAbbVie Inc. (NYSE:ABBV) Shares Purchased by Illinois Municipal Retirement Fundmarketbeat.com - April 22 at 9:59 PMAbbVie (NYSE:ABBV) Trading Up 1.4%marketbeat.com - April 22 at 2:32 PMOLD National Bancorp IN Sells 13,834 Shares of AbbVie Inc. (NYSE:ABBV)marketbeat.com - April 21 at 6:42 PMAbbVie (NYSE:ABBV) Trading 0.2% Higher americanbankingnews.com - April 21 at 3:56 AMCriterion Capital Advisors LLC Invests $2.57 Million in AbbVie Inc. (NYSE:ABBV)marketbeat.com - April 20 at 4:59 PMAbbVie Inc. (NYSE:ABBV) to Post Q1 2024 Earnings of $2.21 Per Share, William Blair Forecastsamericanbankingnews.com - April 20 at 1:46 AMGreenleaf Trust Has $14.84 Million Holdings in AbbVie Inc. (NYSE:ABBV)marketbeat.com - April 19 at 8:50 PMThe Bad News Heading Into AbbVie's First-Quarter Earnings Reportfinance.yahoo.com - April 19 at 3:19 PMAbbVie (NYSE:ABBV) Stock Price Up 0.2%marketbeat.com - April 19 at 12:45 PMWells Fargo Reaffirms Their Buy Rating on AbbVie (ABBV)markets.businessinsider.com - April 19 at 10:18 AMWilliam Blair Research Analysts Decrease Earnings Estimates for AbbVie Inc. (NYSE:ABBV)americanbankingnews.com - April 19 at 3:18 AMAbbVie (ABBV) to Release Earnings on Fridayamericanbankingnews.com - April 19 at 1:20 AMAbbVie Inc. (NYSE:ABBV) Shares Acquired by Xponance Inc.marketbeat.com - April 18 at 4:40 PMAbbVie (NYSE:ABBV) Trading 1.8% Higher marketbeat.com - April 18 at 2:47 PMAbbVie Study on Treatment for Giant Cell Arteritis Meets Primary Endpointmarketwatch.com - April 18 at 1:55 PMAbbVie's Phase 3 Study Of Upadacitinib Achieves Primary Endpoint In Giant Cell Arteritismarkets.businessinsider.com - April 18 at 1:55 PMAbbVie succeeds in late-stage trial for Rinvoq in inflammatory conditionmsn.com - April 18 at 1:55 PMHeard on the Street: AbbVie’s Bet on a Neuroscience Drug Maker Just Got Betterfinance.yahoo.com - April 18 at 1:55 PMAbbVie Q1 Earnings Preview: No Repeat Of Last Year's Q1 Disappointmentseekingalpha.com - April 18 at 1:46 PM Get AbbVie News Delivered to You Automatically Sign up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter. Email Address Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow. Click here for your free guide ABBV Media Mentions By Week ABBV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABBV News Sentiment▼0.640.33▲Average Medical News Sentiment ABBV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABBV Articles This Week▼3822▲ABBV Articles Average Week Get AbbVie News Delivered to You Automatically Sign up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MRK News Today JNJ News Today PFE News Today BMY News Today SGEN News Today IQV News Today IDXX News Today MRNA News Today BNTX News Today ILMN News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ABBV) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the MarketsJeff Bezos Just Humiliated Elon MuskInvestorPlaceDonald Trump Just Predicted "America's Greatest Defeat"Birch Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbbVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
